

#6 JG
08-25-93
PATENT DOCKET 554C1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of
Robert M. Hudziak et al.

Serial No. 08/048,346

Filed: 15 April 1993

For: HER-2 EXTRACELLULAR DOMAIN

) Group Art Unit: 1805
)
) Examiner: M. Mosher
)
)
) 460 Point San Bruno Boulevard
) South San Francisco, CA 94080
) (415) 225-2614
)

RECEIVED
JUL 29 1993
USPTO 1800
1801

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

The following items are supplied to the United States Patent and Trademark Office to advance the prosecution of the subject application.

US Patent No. 4,761,371, Bell *et al.*, issued 02 Aug 1988

US Patent No. 4,968,603, Slamon *et al.*, issued 06 Nov 1990

US Patent No. 4,935,341, Bargmann *et al.*, issued 19 Jun 1990

Hopp *et al.*, "Prediction of protein antigenic determinants from amino acid sequences", *PNAS*, 78(6): 3824-3828 (1981)

Schein, Catherine H., "Production of soluble recombinant proteins in bacteria", *Bio/Technology*, 7: 1141-1149 (1989)

Kane *et al.*, "Formation of recombinant protein inclusion bodies in *Escherichia coli*", *Tibtech*, 6: 95-101 (1988)

Hudziak *et al.*, "Increased Expression of the Putative Growth Factor Receptor p185^{HER2} Causes Transformation and Tumorigenesis of NIH 3T3 Cells", *PNAS*, 84: 7159-7163 (1987)

Akiyama *et al.*, "The Product of the c-erbB-2 gene: A 185 Kilodalton Glycoprotein with Tyrosine Kinase Activity", *Science*, 232: 1644-1646 (1986)

Semba *et al.*, "A v-erbB-related protooncogene c-erbB-2, is distinct from the c-erb-B-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma" *PNAS* 82: 6497-6501 (1985)

Yamamoto *et al.*, "Similarity of Protein Encoded by the Human c-erbB-2 Gene to Epidermal Growth Factor Receptor", *Nature*, 319: 230-234 (1986)



Bargmann *et al.*, "The *neu* oncogene encodes an epidermal growth factor receptor-related protein", *Nature*, **319**: 226-230 (1986)

Coussens *et al.*, "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with *neu* Oncogene", *Science*, **230**: 1132-1139 (1985)

Schecter *et al.*, "The *neu* oncogene: an *erb-B*-related gene encoding a 185,000-M_r tumour antigen", *Nature*, **312**: 513-516 (1984)

Slamon *et al.*, "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/*neu* Oncogene", *Science*, **235**: 177-182 (1987)

Hudziak *et al.*, "p185^{HER2} Monoclonal Antibody has Anti-Proliferative Effects *in Vitro* and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor", *Mol. Cell. Biol.*, abs 105430, **9**(3): 1165-1172 (1989)

Drebin *et al.*, "Inhibition of Tumor Growth by a Monoclonal Antibody Reactive with an Oncogene-Encoded Tumor Antigen", *PNAS*, **83**: 9129-9133 (1986)

Padhy *et al.*, "Identification of a Phosphoprotein Specifically Induced by the Transforming DNA of Rat Neuroblastomas", *Cell*, **28**: 865-871 (1982)

Bernards *et al.*, "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector", *PNAS*, **84**: 6854-6858 (1987)

Drebin *et al.*, "Monoclonal antibodies specific for the *neu* oncogene product directly mediate anti-tumor effects *in vivo*", *Oncogene*, **2**(4): 387-394 (1988)

Drebin *et al.*, "Down-modulation of an oncogene protein product in reversion of the transformed phenotype by monoclonal antibodies", *Cell*, **41**(3): 697-706 (1985)

Drebin *et al.*, "Monoclonal antibodies reactive with distinct domains of the *neu* oncogene-encoded p185 molecule exert synergistic anti-tumor effects *in vivo*", *Oncogene*, **2**: 273-277 (1988)

Yarden *et al.*, "Growth Factor Receptor Tyrosine Kinases", *Ann. Rev. Biochem.*, **57**: 443-478 (1988)

Yarden *et al.*, "Molecular Analysis of Signal Transduction by Growth Factors", *Biochem.*, **27**(9): 3113-3119 (1988)

Yokota *et al.*, "Genetic alterations of the c-*erbB-2* oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-*erbA* homologue", *Oncogene*, **2**: 283-287 (1988)

Zhou *et al.*, "Association of Multiple Copies of the c-*erbB-2* Oncogene with Spread of Breast Cancer", *Cancer Res.*, **47**: 6123-6125 (1987)

King *et al.*, "Amplification of a Novel v-*erbB*-Related Gene in a Human Mammary Carcinoma", *Science*, **229**: 974-976 (1985)

Kraus *et al.*, "Overexpression of the EGF receptor-related proto-oncogene *erbB-2* in human mammary tumor cell lines by different molecular mechanisms", *EMBO J.*, **6**(3): 605-610 (1987)



Van de Vijver *et al.*, "Amplification of the *neu* (c-*erbB-2*) Oncogene in Human Mammary Tumors Is Relatively Frequent and Is Often Accompanied by Amplification of the Linked c-*erbA* Oncogene", *Mol. Cell. Biol.*, **7**(5): 2019-2023 (1987)

Hudziak *et al.*, "Amplified Expression of the HER2/ERBB2 Oncogene Induces Resistance to Tumor Necrosis Factor Alpha in NIH 3T3 Cells", *PNAS*, **85**: 5102-5106 (1988)

Margalit *et al.*, "Prediction of Immunodominant Helper T Cell Antigenic Sites from the Primary Sequence", *J. Immunol.*, **138**(7): 2213-2229 (1987)

Yanisch-Perron *et al.*, "Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors", *Gene*, **33**: 103-119 (1985)

Graham *et al.*, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA", *Virology*, **52**: 456-467 (1973)

Kaufman *et al.*, "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene", *J. Mol. Biol.* **159**: 601-621 (1982)

Shepard *et al.*, "P185^{HER2} Monoclonal Antibody has Anti Proliferative Effects *in vitro* and sensitizes human breast tumor cells to tumor necrosis factor", *J. Cell Biochem.*, p. 42, abs. D253 (1989)

Yarden *et al.*, "Epidermal Growth Factor Induces Rapid Reversible Aggregation of the Purified Epidermal Growth Factor Receptor", *Biochem.*, **26**: 1443-1451 (1987)

One copy of each item cited above is supplied, along with a completed Form PTO-1449. The Examiner is requested to make the citations of record.

This submission is understood to complement the results of the Examiner's own independent search. The submission of this Disclosure Statement should not be construed as a representation that a search was made, or that the cited items are inclusive of all the relevant and material citations that may be available publicly.

The citation of any item is not an admission that the item is prior art. The right is reserved to antedate any item in adherence with standard procedures.

I hereby certify that no item of information in the information disclosure statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign



Page No. 4

application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this information disclosure statement.

Respectfully submitted,
GENENTECH, INC.

Carolyn R. Adler
Carolyn R. Adler
Reg. No. 32,324

Dated: July 9, 1993

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Louise Strasbaugh
Louise Strasbaugh

Date: July 15, 1993